Orchestra BioMed Holdings, Inc.
OBIO · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $33.5M | $2.64M | +1,168% |
| Operating income | −$51.8M | −$64.3M | +19.4% |
| Net income | −$52.7M | −$61.0M | +13.6% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 10, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $100K | $900K | −88.9% |
| Operating income | −$23.3M | −$20.3M | −14.8% |
| Net income | −$18.8M | −$20.8M | +9.6% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Orchestra BioMed's revenue in FY2025?
- $33.5M in FY2025 (Fiscal year ended Dec 31, 2025), +1,168% vs $2.64M a year earlier, per its 10-K filed Mar 2026.
- Was Orchestra BioMed profitable in FY2025?
- No: net income was −$52.7M and operating income −$51.8M in FY2025.
- What was Orchestra BioMed's revenue in Q3 2026?
- $100K (−88.9% vs a year earlier), per its Form 10-Q filed Nov 10, 2026.